CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

Five-Year Clinical Outcomes After Drug-Eluting Stent Implantation Following Rotational Atherectomy for Heavily Calcified Lesions Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation: A Randomised Non-Inferiority Trial Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study

Editorial2017 Oct 1;2(10):1061-1062.

JOURNAL:JAMA Cardiol. Article Link

What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?

Ruel M, Verma S, Bhatt DL. Keywords: PCI; CABG; repeat revascularization

ABSTRACT

Over the last months, 2 major trials and several meta-analyses have been published on the treatment of stable, unprotected left main coronary artery stenosis. Currently, North American and European guidelines for the treatment of left main stenosis indicate a class I recommendation for the performance of coronary artery bypass grafting (CABG). They also indicate a class IIa to III (North American) or a class I to III (European) recommendation for percutaneous coronary intervention (PCI), depending on the complexity of the coronary anatomy as determined by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.